Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Brooks

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
The Journal of Rheumatology|February 17, 2019
Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees DiscussionKathleen M Andersen, Ayano Kelly, Anne Lyddiatt, et al.
The Journal of Rheumatology|August 3, 2011
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare WorkshopClifton O Bingham, Rieke Alten, Susan J Bartlett, et al.
Internal Medicine Journal|October 29, 2017
EVOLVE: The Australian Rheumatology Association's 'top five' list of investigations and interventions doctors and patients should questionKathleen Morrisroe, Ayano Nakayama, Jason Soon, et al.
The Journal of Rheumatology|May 3, 2019
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology TrialsLouise Klokker, Dorthe B Berthelsen, Thasia Woodworth, et al.
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
The Journal of Rheumatology|September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon, C Vibeke Strand, Maarten Boers, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for patient-reported outcomesJohn R Kirwan, Susan J Bartlett, Dorcas E Beaton, et al.
The Journal of Rheumatology|January 17, 2019
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled TrialsKathleen M Andersen, Jonathan T L Cheah, Lyn March, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for imaging and soluble biomarkersMaria-Antonietta D'Agostino, Maarten Boers, John Kirwan, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Rheumatology|February 17, 2019
Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees DiscussionKathleen M Andersen, Ayano Kelly, Anne Lyddiatt, et al.
The Journal of Rheumatology|August 3, 2011
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare WorkshopClifton O Bingham, Rieke Alten, Susan J Bartlett, et al.
Internal Medicine Journal|October 29, 2017
EVOLVE: The Australian Rheumatology Association's 'top five' list of investigations and interventions doctors and patients should questionKathleen Morrisroe, Ayano Nakayama, Jason Soon, et al.
The Journal of Rheumatology|May 3, 2019
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology TrialsLouise Klokker, Dorthe B Berthelsen, Thasia Woodworth, et al.
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
The Journal of Rheumatology|September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon, C Vibeke Strand, Maarten Boers, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for patient-reported outcomesJohn R Kirwan, Susan J Bartlett, Dorcas E Beaton, et al.
The Journal of Rheumatology|January 17, 2019
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled TrialsKathleen M Andersen, Jonathan T L Cheah, Lyn March, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for imaging and soluble biomarkersMaria-Antonietta D'Agostino, Maarten Boers, John Kirwan, et al.
Pageof 6